CompletedPhase 2NCT00770120
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Sai-Hong I. Ou, MD, PhDChao Family Comprehensive Cancer Center
- Intervention
- everolimus(drug)
- Enrollment
- 61 target
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2008 – 2014
Study locations (30)
- Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
- USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP, Marysville, California, United States
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange, California, United States
- Valley Medical Oncology Consultants - Pleasanton, Pleasanton, California, United States
- University of California Davis Cancer Center, Sacramento, California, United States
- San Luis Valley Regional Medical Center, Alamosa, Colorado, United States
- University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States
- Shaw Regional Cancer Center, Edwards, Colorado, United States
- Valley View Hospital Cancer Center, Glenwood Springs, Colorado, United States
- Montrose Memorial Hospital Cancer Center, Montrose, Colorado, United States
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
- Northeast Georgia Medical Center, Gainesville, Georgia, United States
- Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
- Edward Hospital Cancer Center, Naperville, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00770120 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited